Camber Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Camber Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-266,667	Closed	-$21.6M	–	46
2022 Q1	$21.6M	Buy	266,667 +16,667	+7%	+$2.47M	0.78%	29
2021 Q4	$50.7M	Hold	250,000	–	–	1.74%	23
2021 Q3	$67.3M	Buy	250,000 +16,667	+7%	+$4.01M	2.07%	25
2021 Q2	$60.1M	Buy	233,333 +100,000	+75%	+$27.7M	2.02%	24
2021 Q1	$40M	Sell	133,333 -33,334	-20%	-$10.4M	1.37%	24
2020 Q4	$42.5M	Hold	166,667	–	–	1.49%	22
2020 Q3	$41.5M	Sell	166,667 -33,333	-17%	-$10.5M	2.19%	16
2020 Q2	$69.5M	Hold	200,000	–	–	3.98%	9
2020 Q1	$53.5M	Sell	200,000 -50,000	-20%	-$15.5M	3.2%	15
2019 Q4	$80.9M	Buy	250,000 +50,000	+25%	+$14.5M	4.12%	11
2019 Q3	$54.6M	Buy	200,000 +33,333	+20%	+$12.2M	2.87%	17
2019 Q2	$89M	Buy	166,667 +33,334	+25%	+$16.7M	4.15%	7
2019 Q1	$67.2M	Hold	133,333	–	–	3.35%	13
2018 Q4	$65.7M	Buy	133,333 +33,333	+33%	+$20.1M	3.12%	13
2018 Q3	$91.4M	Sell	100,000 -33,333	-25%	-$28.5M	3.91%	9
2018 Q2	$97.7M	Buy	133,333 +33,333	+33%	+$38.4M	3.76%	11
2018 Q1	$159M	Sell	100,000 -123,333	-55%	-$159M	7.83%	2
2017 Q4	$200M	Sell	223,333 -123,334	-36%	-$72.9M	9.79%	2
2017 Q3	$125M	Sell	346,667 -10,000	-3%	-$3.13M	7.91%	2
2017 Q2	$105M	Sell	356,667 -3,333	-0.9%	-$963K	5.09%	6
2017 Q1	$127M	Sell	360,000 -40,000	-10%	-$8.99M	5.14%	5
2016 Q4	$73.6M	Buy	400,000 +186,667	+88%	+$38M	3.83%	8
2016 Q3	$55M	Sell	213,333 -70,000	-25%	-$18M	2.42%	18
2016 Q2	$60.5M	Sell	283,333 -16,667	-6%	-$3.73M	2.92%	15
2016 Q1	$61.9M	Buy	300,000 +66,667	+29%	+$12.8M	3.62%	10
2015 Q4	$59M	Buy	233,333 +83,333	+56%	+$17.1M	3.81%	10
2015 Q3	$24.7M	Buy	150,000 +50,000	+50%	+$8.84M	2.11%	16
2015 Q2	$18.8M	Buy	+100,000	New	+$17.2M	1.28%	25

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Camber Capital Management's NKTR Position: Q2 2022 in Review

Camber Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 266,667 shares — an estimated $21.6M sold.

Camber Capital Management first reported a position in NKTR in Q2 2015 and held it in 28 quarters. The position peaked at $200M in Q4 2017. 228 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Camber Capital Management reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Camber Capital Management sold 266,667 Nektar Therapeutics shares in Q2 2022, an estimated $21.6M.
Camber Capital Management first reported a position in Nektar Therapeutics in Q2 2015 and held it in 28 quarters.
Camber Capital Management's Nektar Therapeutics position peaked at $200M in Q4 2017.
228 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Camber Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.